Moon Nahm, M.D., professor emeritus at UAB Department of Medicine and Director of the World Health Organization's Pneumococcal Serology Reference Laboratory at UAB, discusses his career in pneumococcal immunology. From uncovering the WU2 reference strain and other hidden serotypes to pioneering Multiplexed Opsono-Phagocytosis Assay (MOPA) to measure the functional activity of anti-pneumococcal antibodies, Nahm's contributions have facilitated development of advanced vaccines with broader protection and accessibility.

• UAB Spotlight on Moon Nahm.
• Discovery and Characterization of Pneumococcal Serogroup 36 Capsule Subtypes, Serotypes 36A and 36B. Journal of Clinical Microbiology paper, March 27, 2003.
• A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cpsFragment from an Oral Streptococcus. mBio, May 19, 2020.
• 50 years—and change. WashU Magazine.
• MTM Listener Survey

From leading R&D at a biotech startup company to conducting environmental monitoring for NASA, Veronica Garcia, Ph.D., Scientific Director of the ASM Applied and Environmental Microbiology unit shares how experiences throughout her career have informed her appreciation for microbes and their real-world applications. She also discusses how the ASM AEM unit will support scientists around the globe by fostering collaboration and advocating for scientific advancements in areas like climate change, water systems and food production.

• Prior to her role as Scientific Director for ASM Applied and Environmental Microbiology unit, Garcia was Senior Director of R&D at Boost Biomes, a biotech startup focused on bio-pesticides and bio-fertilizers.
• Garcia's passion for microbiology began studying soil remediation at Texas A&M University.
• Seeing microbes under the microscope for the first time felt like discovering "another world," sparking a lifelong fascination with what microbes are and can do.
• Driven by a desire to see her science make an immediate impact, Garcia was drawn to industry after completing her Ph.D.
• At Boost Biomes, a biotech startup company, Veronica helped transform diverse microbial isolates into bio-pesticides, bio-fertilizers and bio-stimulants for agriculture and food. She progressed from bench scientist to senior Director of R&D, overseeing discovery, genomics, bioinformatics and product development, and learned the realities of scale-up, cost, regulation and end-user needs.
• She also monitored air, water and surfaces for the shuttle and ISS and NASA, ensuring astronaut safety by tracking microbial loads and potential pathogens.
• ASM is organizing around 3 scientific units, ASM Applied and Environmental Microbiology (AEM), ASM Health and ASM Mechanism Discovery.
• These units will equip researchers to translate discovery into impact while providing a forum to collectively shape the future of the field.
• The AEM unit provides the space and unique expertise for microbial scientists and partners to directly contribute to a healthier, more sustainable world through applied and environmental innovation and brings together experts whose work connects microbial processes to outcomes in ecosystems, infrastructure, food systems and planetary health.

• Learn More About ASM's Scientific Units.
• Join the Conversation on ASM Connect, our online community platform.
• Browse Volunteer Opportunities.
• Become an ASM Member.
• Take the MTM listener survey! 

• Dynamics surrounding the AMR crisis are complex and require an understanding of many different perspectives, including those of the farmers, health care professionals, pharmaceutical companies and individuals, in order to foster true and lasting global collaboration on the issue.
• Point-of-care diagnostics are critical to improving treatment decisions and reducing hospital costs.
• Better communication and education are needed in order to rebuild trust in scientists and institutions.
• Continuous research is necessary, as AMR will continue to evolve.
• Citizens are a key piece of the puzzle when it comes to pushing for change and supporting solutions to AMR.

Wilson: "I'll start with actually my Ph.D., which is talking about bacterial antibiotic biosynthesis. And so, I did some work in that arena, but since then, I've actually been working on bacterial protein toxins. These are very potent eukaryotic modulators that when bacteria get into the host, they release these proteins that are very large, that are able to interact with very specific cells. They actually get inside the cells—into the cytosol—and then they affect various signaling pathways in the host that can go anywhere from killing the cell to modulating some of the processes that the cell undertakes, even differentiating them and causing cancer.

So, one of my main focuses in my lab has always been to understand the structure and function of these toxins, to understand how they affect the eukaryotic cell system. And then now that we know a lot about them, we're actually moving more into the direction of trying to basically use them as biologics. We have some platforms that we call bacterial toxin inspired drug delivery, where we're using the mechanisms of how they work and their exquisite specificities to be able to actually use them for therapeutic applications."

Ho: "I got my start doing molecular genetics, actually, with John Mekalanos at Harvard, and I was kind of at the ground floor of the seminal work looking at the Type VI secretion system. And so, I got a front row seat to the kind of discovery and a lot of the initial understanding of the system. And I've kind of taken that work and expanded beyond it to look at kind of the ways different bacteria interact with each other within microbial communities. So my current work is looking at both DNA conjugation as well as the type six antagonism, and how the bacterial interactions kind of work together to build a larger population dynamics and interface with like the hosts that kind of house a your microbial communities."

Antimicrobial Resistance

Wilson: "In 2005 [when the first edition of Revenge of the Microbes was written], there was very little activity or understanding about antibiotic resistance and how important it was. Outside of the field, doctors were encountering it. But oftentimes what was happening is they just said, 'Oh, well, we'll just find another drug, you know.' And pharmaceutical companies, they were recognizing that there was a problem, and they would go off trying to hunt for new ones. And then right around the late 90s, there was a big impetus, because they thought, 'Oh, we, we have a miracle here, because we now do complete genomes. We can get out the comparative genomics and all the high throughput things, all the animations,' and that this would lead to many more new discoveries. And I think the pharmaceutical companies were very disappointed, and they started backing out of what they deemed a huge commitment.

Two decades later, people already were starting to get aware, at least in the field, and even the industry and the physicians. People were getting aware, but I think that they were stumbling, because of their silos, in trying to get interactions with each other. And I think part of it was that they felt that, 'Oh, we can try to solve it ourselves.' And in reality, this is a problem that that is concerning everyone, and everyone is contributing to it. Everyone has to find a solution to help, and we need to have more synergy. There have to be more interactions, and we have to do this at a much more global scale. And so that was sort of what, what we thought when we first started the [2nd edition of the book, Revenge of the Microbes]."

Ho: "At that point, I was just starting my new faculty position, and so I started having to teach students directly. And a lot of students were coming in and giving their presentation on their research proposal or project that they have, and they very adamantly declared the reason why we have antibiotic resistance. 'The problem is because doctors are over prescribing antibiotics.' And I'm scratching my head—a little like, 'Hmm, that's a really confident statement that you're making.' Next student comes in and they're talking about, 'Oh, it's all the farmers that are overusing antibiotics and causing the problem.' And then the next student comes in like, "Oh, the greedy corporations or pharmaceutical industry is trying to milk us for everything, and antibiotics are not profitable enough.' And, and I'm sitting here listening to the students who have a very narrow perspective. And clearly, they're getting it from whoever is teaching their classes.

And so, it feels like every single perspective at every single stage, they only see things through their own eyes, and can't understand what the broader perspective is and why you have all these various different problems, and I guess we call them stakeholders in the thing. It is that that every different angle has its own personal motivations. Corporations do need to have money and persist to exist. Doctors, if you encounter a patient that is dying, well, you have a moral compulsion to actually treat them. And farmers having their livestock, well, their livelihood is at stake if they don't have their animals survive, right?
And so, what I think was really important that we wanted to do is present the problem of antibiotic resistance and the way it works and why it's an issue, but also convey different perspectives on it, so that if people can kind of understand where everybody else is coming from, we can come together and have a more unified perspective, or understanding, at least, so that you're not thinking that everybody is this malicious actor, and you can actually work together to come with up with a complete solution."

Wilson: "The first book, was very important, because you needed to get people's attention right, right? But we got the attention. So, now let's come up with a plan! And we don't have a good plan. People are making progress. People are moving in the directions that need to be moved, coming up with alternatives, coming up with, you know, even financial solutions, to some extent.

They're not enough, still, and it's going to take a global community to come forward and buy in to the problem. And I think we still have a large sector of our whole global community that are not really fully aware of what really this problem entails. They hear on the media and the news, 'Oh, the crisis is here. We're in danger.' And then a year later, they say, 'Well, what happened? Nothing's happened.' It hasn't impacted their lives yet, right? Or at least not in a way that they've noticed. And I think this is why we need more awareness. We need to get the word out there. We need to actually start having folks that make some of the big decisions, both financially, regulatory and other types of things, like education."

Ho: "One really big problem I think that COVID introduced us to, is that it's not just that we have to convince everybody it's important, but we have to also get people, in general, the population, to trust us. You know, that there is a problem. There's been a kind of an erosion in the trustworthiness, or trust in the institutions that we relied upon that are responsible for keeping everybody safe and healthy. And I think a big part of that is also communication education, that the populace needs to be better educated, but the communication level of people in charge, as well as researchers like us—we need to speak to the people in a way that people can understand."

Wilson: "We're not saying that we have a solution, but we do have some directions that, in many areas, have started, and we feel that they need more support. And we're hoping that folks that are reading the book actually appreciate that aspect of it, and then start realizing that, 'Hey, I'm part of this solution too.' It can be very little—being mindful of making sure that we have clean water, making sure that we have food security, making sure that we stay healthy and, therefore, we don't have as many infections, right? Just little things like that that we can actually do as individuals, that as a whole population, will actually contribute to improving the situation.

Then, of course, we have to support our leaders in making some of the decisions. We have to let them know that we care about this. And I think at this stage, what we're hoping is that we can maybe encourage some folks to take a citizen stand on this, to ask questions, to start going and probing and saying, 'Hey, congress person, what are you doing about this?' And maybe just start the dialog. This is all we're doing, is starting a dialog."

• The 2nd Edition of Revenge of the Microbes, details the intricacies of the antibiotic-microbe arms race. Beginning with a historical perspective on antibiotics and their profound impact on both modern medicine and present-day society. It also examines the practices and policies driving the discovery and development of new antibiotics, what happens to antibiotics once they are released into the environment, how antibiotic-resistant bacteria evolve and spread and the urgency for finding alternative approaches to combating infections. For anyone interested in antimicrobial resistance (AMR), this is a completely approachable 360-degree view of a very complex topic. Get your copy of Revenge of the Microbes today!
• Want to get involved and spread the word about AMR? Become an ASM Advocate
• Bacterial Pathogenesis: a Molecular Approach
• Take the MTM listener survey!

Sabra Klein addresses the question: how does biological sex influence influenza infection and vaccination? She explains her findings on inflammation differences between males and females, and how these differences can affect the outcome of disease. Klein also discusses her advocacy for inclusion of biological sex in method reporting as a means to improve scientific rigor.

Host: Julie Wolf

Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the ASM Podcast app.

Julie's biggest takeaways:

• Information from the 1918 influenza pandemic suggested males died at a higher rate than females, which could be due to a gender fator or a biological factor. In 1918, men lived in close quarters of military barracks while women didn't, representing a cultural difference of gender norms (women were exempted from military duty). But males are more susceptible to secondary bacterial infections that often accompany flu, which may represent a biological difference in infection outcome. In Klein's studies, female mice suffer influenza more severely than males. Women who contracted the H1N1 flu epidemic in 2009 were more likely to be hospitalized with severe influenza than men. These data have yet to be aligned and leave many variables yet to explore!

• Influenza infection disrupts the female menstrual cycle, causing lowered estrogen and progesterone levels. Providing exogenous progesterone can dampen inflammation and stimulate repair mechanisms needed to fix the damaged lung tissue. This type of host treatment is less likely to lead to the evolution of resistance than using antiviral compounds.

• Females and males respond differently to vaccination; females mount a higher antibody response and have greater cross-protection than males.

• Many diseases in addition to influenza show these sex-specific differences. The sex differences observed are specific to age; with older age, the differences are lost.

• In several other countries, epidemiological and clinical data are analyzed for differences between sexes. With greater awareness, the United States may incorporate this practice too.

   

Featured Quotes (in order of appearance):

"Both genes as well as the hormones define the biological construct of sex."

"There's an ample amount of data that suggest men are less likely to wash their hands than women. We all know handwashing is probably one of the best ways to avoid contact with viruses - really anything infectious. We always have to question if we do things that influence our exposure; but in our mice studies, we can control their exposure."

"We really have a love-hate relationship with inflammation. We need it to recognize the presence of the virus, but then we need it to dissipate. Our data suggest hormones are integral to regulating inflammation and the repair following inflammation."

"The immune responses to the influenza vaccine - and this extends to many vaccines - are often higher in females as compared with males. This has been shown in humans as well as animal models."

"I don't know that I think that man flu is real. I think a lot can depend on both your age as well as your vaccine status that can influence whether you're going to land in the hospital with severe influenza. Much like we were talking about with individuals who don't have a vaccine, such as during a pandemic, females may be suffering a bit more, but once vaccinated females seem to do better than males. There are some nuances we shouldn't lose sight of."
 

Links for this episode

• Sabra Klein website
• Klein speaking on heart disease differences in men and women
• Klein editorial in mBio: Sex reporting in microbiological and immunological research
• Smithsonian exhibit notification
• HOM Tidbit: Smithsonian article: How the horrific 1918 flu spread across America
  
• HOM Tidbit: Aeon article: Who names diseases?

Send your stories about our guests and/or your comments to jwolf@asmusa.org.

Jennifer Martiny describes the incredible microbial biodiversity of natural ecosystems such as soils and waterways. She explains how to add a bit of control in experiments with so many variables, and why categorizing microbial types is important for quantifying patterns.

Host: Julie Wolf

Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the ASM Podcast app.

Julie's biggest takeaways:

• Studying microbial community functions in their natural environment are harder to understand, but help us to parse the complexity of the natural world, in part because these experiments also include local flora and fauna that are often omitted in the controlled lab environment. Microbial cages - an actual physical barrier that contains a soil-based community - can help to disentangle the effects of the microbial community from those of the surrounding environment by adding a level of control by limiting interaction of microbes inside the nylon mesh cage with those outside of it.

• Are microbial functions redundant? It depends on what function you look at - respiration is a very common function, so it's less likely to be affected by a change in microbiome composition. Other functions, such as degrading particular compounds, may have a stronger relationship between the microbes present and those functions.

• Microbes are hugely diverse! Jennifer's comparison of all the diversity of the birds on Earth to a single bacterial taxon is mind-blowing!

• Microbial categorization may be hard, but the ability to group similar organisms is necessary to formulate hypotheses and conduct experiments. It's important to remember the groupings are manmade and sometimes have to be reconstructed!

Featured Quotes (in order of appearance)

"One of the hardest things we study is not on the microbiology side but is on the ecosystem side, measuring those biochemical functions in the environment." (10:05)

"It's not as if we are ever going to be able to study every particular organism out there and build a model with thousands of equations; instead what we really need to do is go after trade-offs and overall relationships that may hold across large groups, and in that way have some simple rules under different conditions like drought or temperature." (16:45)

"Modern birds evolved about 100, 125 million years ago. Two sequences that share the 16S gene, if it's roughly 97% identical, probably diverged 150 million years ago. That means we are lumping in all the diversity within the bacteria group within one taxon, calling it a species, which is the equivalent of lumping all birds together!" (18:47)

"It's a bit overwhelming to imagine that for each 16S rRNA taxon, you could have as much functional, morphological, and behavioral diversity as what we see in all of birds!" (19:39)

"In biology, we're always using an operational definition but we don't want to get too hung up on the definition and miss all the interesting patterns going on!" (20:49)

"If you can start to quantify patterns, then you can start to ask ecological and even evolutionary questions about why we see those patterns." (33:04)
 

Links for this episode

• Jennifer Martiny Lab Home Page

• University of California Irvine Microbiome Initiative

• HOM Tidbit: TWIM 50: These things aren't even bacteria!

• Carl Woese Obituary (New York Times)

• Carl Woese 1996 Feature (New York Times)

Send your stories about our guests and/or your comments to jwolf@asmusa.org.

Peter Hotez talks about neglected tropical diseases: what are they, where are they found, and where did the term "neglected tropical disease" come from, anyway? Hotez discusses some of the strategies his and other groups are using for vaccine development, and his work as an advocate for childhood vaccines and global health.

Host: Julie Wolf

Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the ASM Podcast app.

Julie's biggest takeaways:

• Renaming "other diseases" - a large collection of disparate diseases such as schistosomiasis, leishmaniasis, and onchocerciasis (also called river blindness) - as "neglected tropical diseases" by Hotez and colleagues was integral to bringing attention to the diseases of the bottom billion, people that live on less than one U.S. Dollar per day.

• Neglected tropical diseases are often chronic and debilitating without high mortality. These diseases trap people in poverty due to their long-term effects. The NTDs are often associated with terrible stigma that can lead to additional challenges for affected populations.

• Neglected tropical diseases are found worldwide, in rich and poor countries. The poorest peoples living in the G20 countries (and Nigeria) now account for most of the world's NTDs.

• Parasitic infections present challenges for vaccine design, but reverse vaccinology may be a useful strategy. Reverse vaccinology mines genomes to identify promising vaccine candidates in silico, which are then narrowed sequentially for those that are expressed on the bacterial surface, immunogenic, and ultimately protective against disease. This strategy has worked for Neisseria meningitidis, and Hotez is hopeful that it will produce effective vaccines for the parasitic infections he studies.

• The tradition of individual fields and departments, combined with the old-fashioned notion that scientists needn't spend their time engaging with the public, has led to flatlined budgets and the rise of anti-science movements. Scientists need to engage the public to ensure the future of science and science-based policy.

   

Featured Quotes (in order of appearance):

"The concept of 'neglected tropical diseases' was very much born out of the Millennium Development Goals launched in the year 2000."
 

"Treating NTDs in rich countries "is not a resource problem; it's an awareness problem."

"If you want to enter global health, we need as many people with a scientific background to go into business and law and international relations as we need to go into traditional scientific pathways"
 

"Many involved in the antivaccine movement disproportionately involve either parents who are affluent or educated, or both: those who know just enough to do a google search but without the background to separate the garbage from the important stuff. And of course the anti-vaccine groups are deliberately misleading."
 

"Research America found that 81% of Americans can't name a living scientist. That's our fault. We're so inward looking that we aren't taking the time to do public engagement."
 

Links for this episode

• Peter Hotez at Baylor College of Medicine
• Peter Hotez website
• Millennium Development Goals published by the World Health Organization in 2000
• WHO list of Neglected Tropical Diseases
• Forgotten People, Forgotten Diseases by Peter Hotez
• Blue Marble Health by Peter Hotez
• Public Health United episode featuring Hotez
  
• HOM Tidbit: Oncocerciasis now: 1986 British Medical Journal report

Send your stories about our guests and/or your comments to jwolf@asmusa.org.

Stacey Schultz-Cherry explains the selection process to choose the influenza virus strains to include in the annual influenza vaccine. Schultz-Cherry also discusses her research on the influence of obesity on the course of disease and vaccine efficacy.

Host: Julie Wolf

Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the ASM Podcast app.

Julie's biggest takeaways:

• The WHO Collaborating Centers and National Influenza Centers around the world work with a humongous network of physicians, public health workers, and veterinarians to identify strains most likely to become part of the circulating influenza viruses.

• An influenza strain that makes birds very sick is not necessarily a strain that will make people sick.

• Predicting phenotype from genotype remains a challenge. Receptor binding to mammalian receptors, signatures in the genome that allow it to replicate in mammalian cells, and transmission between ferrets are the marks of potentially bad strains. Genetics can also tell you a little bit about the antiviral resistance characteristics of a strain.

• Why can't we incorporate all known influenza strains into a vaccine? It's an issue of immunodominance - having enough antibodies against an infectious agent that it will be neutralized should it cause infection. Researchers don't know how many HAs you can incorporate to generate proper immunity to each molecular version, and this is one area of influenza vaccine research.

• Obesity appears to decrease the immune response to influenza, potentially affecting the ability to form memory response. This means the vaccine is less effective, the course of disease when infected is worse, and the likelihood of secondary bacterial infection is higher.

Featured Quotes (in order of appearance)

"People don't appreciate how much work goes into this. The importance of surveillance - if we lose our surveillance, it's going to be very difficult to know which strains to select for the vaccine, as well as diagnostics."
 

"Part of the trick is not just predicting which viral strain to use but understanding which of those strains will grow to the highest efficiency without changing when we grow it in eggs to make the vaccine."
 

"My bet is, whatever we find, it's going to end up being 10 times more complicated...which is great for my post-docs, because there's plenty of opportunities for them to find new things and build new labs, which is ultimately the most important thing you can do as a P.I."
 

"I did wound repair during my Ph.D. . . . with my background in wound repair, I said 'what is a virus but a great big wound" 
 

"When I was changing fields, my thesis committee asked me, 'what are you doing? I was told it would take five years just to read the literature. You can't change fields!' And I said, 'Yeah, I can.'" And I did!
 

"Whatever your decision is, you go for it you don't have regrets, but you put 110% into whatever you decide to do."
 

Links for this episode

• Stacey Schultz-Cherry
• St. Jude Graduate School of Biomedical Sciences
• CDC Flu Activity Map
• HOM Tidbit: Vaccination against Influenza (review)

Send your stories about our guests and/or your comments to jwolf@asmusa.org.

Gigi Kwik Gronvall talks to MTM about the importance of biopreparedness. Gronvall discusses her work in creating policies around potential natural, accidental, and man-made pandemics. She describes her experiences running pandemic thought exercises that help researchers, public health workers, and governmental officials apply preparedness ideas to real-world simulations.

Host: Julie Wolf

Julie's biggest takeaways:

• Thought exercises and scenarios work well for people to understand how technology, communications, human behaviors can affect the spread of infectious disease.

• Many after-action reports after major biosecurity breaches, such as the Dugway contamination event, where inactivated Bacillus anthracis was accidentally shipped without being inactivated. These involve reports on what went wrong, who made mistakes, and how to prevent repeats of these errors going forward.

• International groups such as the Global Health Security Alliance work with governments and institutions around the world to run dialogs and talk about biosecurity issues, safety issues, pathogen management issues. Comparing notes across countries helps to harmonize policies and find gaps that need addressing.

• Bringing scientists into the policy-making meetings is the best way to write regulations in a way to protect the public, the scientists, and the research itself. Crafting good recommendations for governance prevents writing regulations that can be hard to remove.

Featured Quotes (in order of appearance):

"There's a public health infrastructure that's needed to detect epidemics and respond to them appropriately. If you are lacking that infrastructure, it's like not having a fire department anywhere close when there's a fire. The fire gets bigger and bigger, it becomes much more difficult to be able to put out the fire, and a lot of lives are lost."

"The thinking behind the GHSA is to boost public health infrastructure in different parts of the world that need it and to focus donor attention on some of those areas so that the weakest links are made stronger."

"It's going to shock no one, but it's not always the case that the best scientific information is brought to bear on a policy issue."

"You have to do what you can to make things a little bit harder, a little bit more challenging but still allow real, legitimate, important science to continue. Everybody sees that balance a little bit differently."

"It's important to me that we have someone advocating for the science and making it so it's not onerous to be a scientist."

"Synthetic biology changes the way we think about what biology can do. Biology has a bigger potential to be involved in industrial processes than it used to have."

"The problem with a lot of these pathogens is that they exist in nature...you can't take care of all options, unfortunately."

"You can't ever be fully prepared, but you can be in the right mindset to be surprised."

Links for this episode

• Gigi Kwik Gronvall website at Johns Hopkins University
• SPARS epidemic pamphlet
• Preparing for Bioterrorism: The Alfred P Sloan Foundation's Leadership in Biosecurity: Book by Gronvall
• Synthetic Biology: Safety, Security, and Bioterrorism: Book by Gronvall
  
• The Global Health Security Alliance homepage

Send your stories about our guests and your comments (email or recorded audio) to jwolf@asmusa.org.

Jack Gilbert talks about his studies on microbiomes of all sorts. He describes the origin of the Earth Microbiome Project, which has ambitions to characterize all microbial life on the planet, and talks more specifically about the built microbiome of manmade ecosystems such as hospitals. Gilbert explains how advances in scientific techniques have driven past microbiome-related discoveries and will continue to do so in the future.

Host: Julie Wolf

Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the ASM Podcast app.

Julie's biggest takeaways:

1. Insect-pathogenic fungi living in plant roots can pass nitrogen from killed insects to their plant hosts, receiving different carbon nutrients from the plants in return.

2. Fungi harvested after growth on inexpensive materials like chicken droppings are used in agriculture both as fertilizer and as insecticide.

3. Cyclosporine was first discovered in insect-pathogenic fungi.

4. Raymond St. Leger and other scientists working to introduce genetically modified microbes into the environment deeply consider the societal effects of their work, including collaboration with local communities, governmental regulatory bodies, and trusted leaders and tailor their efforts to the regional area.

Featured Quotes (in order of appearance):

"We really can apply ecological understanding of microbiomes and microbial ecosystems to any environment."

"I think basic research is absolutely essential but I always want to think about what that could lead to in the future."

"Reproducibility is key and extraordinarily difficult in all fields of science due to lack of appropriate funding and a zeitgeist in science that discourages scientists from reproducing one another's studies."

"We are forever striving to validate the predictions we derive from our descriptive work. We create SO MANY predictions!"

"No small dreams, no small goals - go big or go home! At the end of the day, we all want to feel like we're doing something that makes an impact."

"I love to collaborate. I love to work with other people, brilliant people in the microbiome field"

"I'm often accused of not being focused enough. What does Jack Gilbert do? Well, I do a little bit of everything - as long as there's a microbe involved! I like it like that; it keeps me energized."

Links for this episode

• Jack Gilbert website at University of Chicago
• Jack Gilbert TedxNaperville Talk
• Earth Microbiome Project home page
• Dirt is Good - new book by Gilbert and Rob Knight
• History of Microbiology Tidbit: Joshua Lederberg piece in The Scientist on 'microbiome' nomenclature in 2001.

Send your stories about our guests and your comments (email or recorded audio) to jwolf@asmusa.org.

Tara C. Smith discusses her work uncovering ties between agriculture and methicillin-resistant Staphylococcus aureus (MRSA). Her studies have found MRSA on and around pig farms, on animal handlers, and even in packaged meat in the grocery store. She also talks about using zombies as an allegory for infectious disease outbreak preparedness.

Links for this episode

Tara C. Smith website

Aetiology Blog on Science Blogs Network

Outbreak News Interview with Smith on her work communicating the science around vaccines and fighting anti-vaccine sentiments.

Smith's collected writings on Ebola and emerging infectious diseases

Zombie Infections: Epidemiology, Treatment, and Prevention in the British Medical Journal

History of Microbiology tidbit: Thomas Jukes' 1968 Letter to the British Medical Journal and 1997 Recollections in Protein Science.

Julie's biggest takeaways:

MRSA transitioned from primarily hospital-acquired to community-acquired infections in the 1990s. In the early 2000s, MRSA strains associated with livestock farming emerged in Europe. Smith's group was the first to identify agriculture-associated MRSA strains in the United States.

Tara found MRSA on the very first farm in which she and her colleagues looked for MRSA.

The MRSA strain ST398 appears to have originated in people as MSSA then moved to livestock, where the strain acquired some antibiotic resistance related genes. This is because zoonotic diseases are a two-way street and microbes can pass from people to animals, as well as passed from animals to people.

Many factors may contribute to MRSA contamination of consumer meat products: for one, MRSA in farms is aerosolized and the same may be true in meat processing facilities. People can also be colonized and spread from workers to products. It's likely a mixture of strains from farms and strains from people working in the packing plants.

Farms that raise animals without antibiotics were not positive for MRSA. Processing these animals at plants where conventional animals are raised creates potential for cross-contamination, however.

Prophylactic and treatment applications of antibiotics are still allowed for livestock, but antibiotics used for growth promotion purposes were phased out in January 2017.

Featured quotes:

"I was in Iowa, the #1 pig-producing state. We started looking for MRSA + found them on the very 1st farm we sampled"

"When we think of zoonotic diseases, usually we think of microbes that come from animals to people, but there can be bidirectional transmission. It's definitely not just a one-way street

"That it doesn't cause disease in pigs made S. aureus invisible to people studying its epidemiology for quite a while"

"Our biohazard people probably hated us because we had pounds and pounds of meat products we were checking" for MRSA

"S. aureus is definitely not the only one - there's lots of bacteria that are affected by use of antibiotics on farms"

"Everything zombies now is a virus!" 

Raymond St. Leger describes his work on insect pathogenic fungi. Members of this diverse group of fungi can be found as part of the plant rhizosphere, where they provide nutrients to the plant, and can also be deployed as insect control agents. Raymond discusses his work with communities in Burkina Faso, where he works with officials to educate and gain consent for use of mosquito-killing fungi to control the spread of malaria.

Host: Julie Wolf

Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the Microbeworld app.

Julie's biggest takeaways:

1. Insect-pathogenic fungi living in plant roots can pass nitrogen from killed insects to their plant hosts, receiving different carbon nutrients from the plants in return.

2. Fungi harvested after growth on inexpensive materials like chicken droppings are used in agriculture both as fertilizer and as insecticide.

3. Cyclosporine was first discovered in insect-pathogenic fungi.

4. Raymond St. Leger and other scientists working to introduce genetically modified microbes into the environment deeply consider the societal effects of their work, including collaboration with local communities, governmental regulatory bodies, and trusted leaders and tailor their efforts to the regional area.

Featured Quotes:

"Possibly fungi kill more organisms than any other disease-causing agents." (2:55)

"People are interested in how you can utilize a plant-root colonizing Metarhizium as a comprehensive biofertilizer." (14:30)

"Put elite Metarhizium onto corn seeds and you can boost the growth of corn by about 30%." (14:50)

"Mosquitos and malaria have no friends." (23:17)

"If an insect is especially common, then a strain of Metarhizium will specialize to that insect." (24:35)

"There's a lot of different ethical, political, and social concerns we have to address and we have to resolve before any type of genetically manipulated product can be introduced. We even have questions about the meaning of informed consent!" (28: 30)

"Synbio-phobia-phobia: the belief that genetic engineers have that people are going to be frightened of their work."(32:00)

"In Burkina Faso, you can expect to get more than 200 bites from Anopholes gambiae a day. This is malaria central." (37:58)

Links for this episode

• Raymond St. Leger website at the University of Maryland
• St. Leger lab research explained in a three-minute video
• NPR story covering fungal pesticides as alternatives to chemicals
  
• Discover Magazine blog on malaria-fighting Frankenfungus
• CHOMA tidbit: Felix d'Herelle and the Origins of Molecular Biology by Bill Summers (Excerpt of Chapter 3. Epizootics: Locusts in Argentina and Algeria).

Send your stories about our guests and/or your comments (email or recorded audio) to jwolf@asmusa.org.

Vincent Racaniello discusses how he ended up studying polio virus and the three eureka moments he's experienced so far: uncovering the polio genome, discovering the polio receptor, and generating a mouse model of polio disease. Vincent discusses his interest in science communications, including his blog and active podcast network.

Host: Julie Wolf

Activities of the National Foundation for Infantile Paralysis in the Field of Virus Research (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the Microbeworld app.

Julie's biggest takeaways:

1. All three polio virus serotypes are covered by the polio vaccine; type 2 has been eradicated and type 3 is close to being eradicated.
2. Enterovirus 68 is a related enteroviruses that is associated with paralysis, but its receptor and disease progression remain largely unknown.
3. Developing tools and techniques to study one virus that can cross into the central nervous system, such as polio, can set up a lab to study other neurotropic viruses, such as enterovirus 68 and Zika virus.
4. All scientists with access to a computer and a social media account can be effective science communicators!

Featured Quotes:

"You have to find people to be mentors who you are going to listen to, and if they give you advice, you follow it." (6:57)

"It took me one year to sequence the genome of polio, which you could do in five minutes today." (9:52)

"We work on infectious agents and a big part of it is to eradicate them and alleviate human disease." (20:32)

"On facebook, you've lots of friends who are following you; if you show them science, some of them will listen to it." (33:30)

"We all have to share what we do. We're funded mostly by tax dollars, and we have to let the public know what we do." (34:00)

Links for this episode

• Vincent Racaniello
• Zika Diaries: a blog about the Racaniello lab experiences studying Zika Virus
• Virology Blog
• This Week in Virology
• Scientists: Engage the Public!
• CHOMA tidbit: Activities of the National Foundation for Infantile Paralysis in the Field of Virus Research by Paul de Kruif

Send your stories about our guests and/or your comments (email or recorded audio) to jwolf@asmusa.org.

Welcome back, Meet the Scientist subscribers! For those of you who never heard an episode of Meet the Scientist, thanks for taking a listen. We're excited to tell all of you we're now Meet the Microbiologist (MTM). MTM is the same great, one-on-one conversations captured in Meet the Scientist just with a new name and a new host. 

Julie Wolf of the American Society for Microbiology will be bringing back the podcast with all new episodes with scientists who work in one of the many areas of the microbial sciences — genomics, antibiotic resistance, virology, synthetic biology, emerging infectious diseases, microbial ecology, public health, probiotics, and more!

The first two new episodes will be released September 28th, beginning with an episode with Vincent Racaneillo of This Week in Microbiology taking about his research on polio and Zika virus, and his experience as a science communicator. The other episode, released the same day, is with Raymond St. James discussing applications of insect-pathogenic fungi as plant fertilizers and mosquito control agents. 

Make sure to subscribe, for free, wherever you listen to podcasts including iTunes, Android, or get each episode delivered by email. Subscribing to the podcast is the best way to make sure you never miss an episode!

Talk to you soon!

Joseph James, biologist at the U.S. Environmental Protection Agency, discusses his career trajectory and the creation of Binning Singletons, a unique mentorship program built on peer-to-peer networking at scientific meetings and conferences and was first implemented in 2019 at ASM Microbe.

• Learn more about Binning Singletons.
• Contact Joe James: Joe@binningsingleton.com
• Follow Binning Singletons on Bluesky.
• Binning Singletons: Mentoring through Networking at ASM Microbe 2019—mSphere article.
• Binning Singletons: Tackling Conference Networking When You Don't Know Anyone—Guest post on Addgene Blog.
• Mastering a Mentoring Relationship as the Mentee—asm.org article that James says has really helped him explain Binning Singletons as a coaching form of mentorship.
• Mapping a Mentoring Roadmap and Developing a Supportive Network for Strategic Career Advancement—article on developing networks of mentors, another area Binning Singletons tries to address.
• #FEMSmicroBlog: Networking at Online Conferences (for Early Career Scientists).
• Take the MTM listener survey!

• Dietary lead modulates the mouse intestinal microbiome: Subacute exposure to lead acetate and lead contaminated soil.
• In situ differences in nitrogen cycling related to presence of submerged aquatic vegetation in a Gulf of Mexico estuary.
• Quantifying stream periphyton assemblage responses to nutrient amendments with a molecular approach.
• Analysis of Bacterial Communities in Seagrass Bed Sediments by Double-Gradient Denaturing Gradient Gel Electrophoresis of PCR-Amplified 16S rRNA Genes.
• Use of composite data sets for source-tracking enterococci in the water column and shoreline interstitial waters on Pensacola Beach, Florida.

In this podcast, I speak to Martin Blaser, Frederick H. King Professor of Internal Medicine and Chairman of the Department of Medicine and Professor of Microbiology at the New York School of Medicine. Blaser studies Helicobacter pylori, bacteria that live in the stomachs of billions of people. Blaser has shown that H. pylori has a strange double life inside of us. On the one hand, it can cause ulcers and gastric cancer. On the other hand, it can protect us from diseases of the esophagus, allergies, asthma, and perhaps even obesity. We're now eradicating H. pylori with antibiotics and other luxuries of modern life; Blaser thinks we ought to bring it back--but keep it on a tight leash.

All life hums with electricity, from our heartbeats to the electrons that flow to the oxygen we breathe.But some bacteria are electricians par excellence, generating electric currents in the soil and water.

In this podcast, I talk to microbe-electricity expert Jeff Gralnick of the University of Minnesota about the biology behind these currents, and how engineers may be able to harness it to power technology.

In this podcast I talk to Jessica Green of the University of Oregon about aerobiology: the science of life in the air.

We live in an invisible ocean of life, with millions of microbes swarming around us. Microbes can live many miles high in the upper atmosphere, and they may actually be able to feed and grow in clouds. Green and I talk not just about high-altitude aerobiology, but about the microbes we share our homes and offices with, and how better understanding them can help our health.

In this podcast, I talk to Charles Bamforth of the University of California, Davis, about the surprisingly complex chemistry of beer, and the pivotal role microbes play in making it happen.

In this podcast I talk to Thomas Scott of the University of California, Davis, about dengue fever, a disease that's on the rise. Spread by mosquitoes, it can make you feel as if your bones are broken and leave you exhausted for months. In more serious cases, people suffer uncontrollable bleeding and sometimes die. Dengue is expanding its range, and is even making incursions into the United States. Scott and I talk about what scientists know and don't know yet about dengue, and what the best strategy will be to drive the virus down.

In this podcast I talk to Charles Ofria, a computer scientist at Michigan State University.

Ofria and his colleagues have created a program called Avida in which digital organisms can multiply and evolve. They are studying many of evolution's deepest questions, such as how complexity evolves from simplicity and why individuals make sacrifices for each other. The evolution unfolding in Avida is also yielded new software that can run robots and sensors in the real world.

Bonus Content includes:

Avida Movie

In this movie, we started with a normal Avida organism in the middle of the population and let it grow for a while before injecting a highly-virulent parasite into the middle.  The hosts are all colored with shades of blue and the parasites are shades of red.

In this podcast I spoke to David Baker, a professor of biochemistry at the University of Washington. Baker and his colleagues study how proteins fold, taking on the complex shapes that make our lives possible.

It turns out that protein folding is a fiendishly hard problem to solve, and even the  most sophisticated computers do a poor job of solving it. So Baker and his colleagues have enlisted tens of thousands of people to play a protein-folding game called Foldit. I talked to David Baker about the discoveries they've made through crowdsourcing, and the challenges of getting 57,000 co-authors listed on a paper.

Additional Resources:

Rosetta@Home

Foldit

It never occurred to me that the human body and a coral reef have a lot in common--until I spoke to Forest Rohwer for this podcast. Rohwer is a microbiologist at San Diego State University, and he studies how microbes make coral reefs both healthy and sick. Just as we are home to a vast number of microbes, coral reefs depend on their own invisible menagerie of algae and bacteria to get food, recycle waste, and fend off invaders. But as Rohwer writes in his new book, Coral Reefs in the Microbial Seas, we humans have thrown this delicate balance out of kilter, driving the spread of coral-killing microbes instead.

Additional Reading:

Viral communities associated with healthy and bleaching corals.
The lagoon at Caroline/Millennium atoll, Republic of Kiribati: natural history of a nearly pristine ecosystem.
Metagenomic analysis of stressed coral holobionts.

In this podcast, I talk to Susan Golden, the co-director of the Center for Chronobiology at the University of California at San Diego.

We talked about Golden's research into time--in particular, how living things know what time it is. While you may have heard of our own "body clock" that tracks the 24-hour cycle of the day, it turns out that some bacteria can tell time, too. Golden has discovered how evolution has produced a molecular clock inside microbes far more elegant than any manmade timepiece.

Additional Reading:

Quinone sensign by the circadian input kinase of the cyanobacterial circadian clock

How many genes can a species lose and still stay alive? It turns out, bacteria can lose just about all of them!

In this podcast, I talk to Nancy Moran of Yale University about her fascinating work on the microbes that live inside insects such as aphids and cicadas. After millions of years, they have become stripped down creatures that are revealing some profound lessons about how superfluous most genes are--at least if you live inside a host.

Recent Publications:

Bacterial genes in the aphid genome: absence of functional gene transfer from Buchnera to its host

Symbiosis and insect diversification: an ancient symbiont of sap-feeding insects from the bacterial phylum Bacteroidetes

Saeed Khan, Ph.D., Head of the Department of Molecular Pathology at Dow diagnostic research and reference laboratory and President of the Pakistan Biological Safety Association discusses the importance and challenges of biosafety/biosecurity practices on both a local and global scale. He highlights key steps for biorisk assessment and management and stresses the importance of training, timing and technology.

• Adequate biosafety and biosecurity protocols depend on a thorough understanding of modern challenges, and scientists must be willing and able to respond to new technological threats appropriately.
• In the microbiology lab, the threat goes beyond the physical pathogen. Implications of genomics and cyber security must be built into biorisk management techniques, including data storage and waste management practices.
• Risk assessments involve evaluation of both inherent and residual risk.
• Inherent risk is linked to the pathogen.
• Residual risk varies according to the lab, equipment, employee, environment, etc.
• As a result, biosafety and biosecurity risks are constantly changing, and assessments must be repeated strategically and often.
• Khan recommended repeating a risk assessment whenever a key variable in the equation changes, i.e., new equipment, new employee, new pathogen. He also recommended (at minimum) conducting routine risk assessments every 6 months, or twice a year.

"We need to have basic biosafety and biosecurity to stay away from these bugs and the modern challenges, like cyber biosecurity and genomics. These are the new areas, which are potential threats for the future, and where we need to train our researchers and students."

"Starting from simple hand washing or hand hygiene, the basic things we use are gloves, goggles and PPE to protect the workers, the staff and the patient from getting infected from the environment, laboratory or hospitals. These are the basic things, and it's very crucial, because if one is not using gloves in the lab or not wearing the lab coat, he or she may get infected from the sample, and the patient can get infected from the physician and doctors or nurse if they are not following the basic biosafety rules. These [things] are routinely important. Every day we should practice this."

"But there are [also] new challenges. Particularly in the microbiology lab, we [used to] think that once we killed the bacteria, then it's fine. But nowadays, it's not the way we should think about it. Though you kill the bacteria practically, it still has a sequence, [which] we call the genome, and if you have that information with you, you theoretically have the potential to recreate that pathogen… that can be used or maybe misused as well."

"[Working with] scripts of pathogens, like smallpox or the polioviruses, we call this synthetic biology. Different scientists are doing it for the right purposes, like for production of vaccines, to find new therapeutics, to understand the pathology of the diseases. But on [the other hand]—we call it dual use research of concern (DURC)—the same can be misused as well. That's why it's very important to be aware of the bugs that we are working with, and the potential of that pathogen or microbe, to the extent that can be useful or otherwise."

"So, we should be aware of the new concern of the technology, synthetic biology and DURC. These are new concepts—cyber, biosecurity and information security [are all] very much important these days. You cannot be relaxed being in the microbiology lab. Once we have identified a pathogen, declared a result to the patient and the physician, and it's been treated, we [still] need to be worried about waste management—that we discard that waste properly and we have proper inventory control of our culture. It should be safe in the locker or on in the freezers and properly locked, so we should not be losing any single tube of the culture, otherwise it may be misused."

Risk Assessment

"The best word that you have used is risk assessment. So, it should gage the severity of the issue. We should not over exaggerate the risk, and we should not undermine the risk. Once the risk assessment been made, we can proceed."

"Right from the beginning of touching a patient or a sample of the patient until the end of discarding the sample, that is called biorisk management. It's a complete science that we need to be aware of—not in bits and pieces. Rather a comprehensive approach should be adopted, and each and every person in the organization should be involved. Otherwise, we may think [we are] doing something good, but someone else may spoil the whole thing, and it will be counterproductive at the end."

"We should involve each and every person working with us and the lab, and we should empower them. They should feel ownership that they are working with us, and they are [as] responsible as we are. So, this the whole process needs to be properly engaged. People must be engaged, and they should be empowered, and they should be responsible."

"Each and every lab has different weaknesses and strengths of their own, which play an important role in the risk assessment."

"There is inherent risk, which is linked with the pathogen, and there is another thing we call residual risk. So, residual risk everywhere and varies. Though the inherent risk may be the same, the residual risk is based on the training of the person, the lab facility that is available, the resources that labs have and the potential threats from the environment."

"It's not usually possible that you do a risk assessment every day. So, when you have different factors involving a new pathogen in your lab, you have new equipment in your in your lab, or some new employee in your lab—[a new] variable factor that is involved—you should [perform] the risk assessment. Otherwise, [a routine risk assessment] should [be done] twice a year, after 6 months."

"Training is important, and response time is very much crucial. And different technology plays a vital role, but the lack of technology should not be an excuse for not responding. There is always an alternative on the ground that you may do the risk assessment. And within the given resources and facility, we should mimic the technology and respond to any outbreaks or disease within our given resources."

• ASM Guidelines for Biosafety in Teaching Laboratories
• Pakistan Biological Safety Association
• Training to be a Biosafety Professional (video)
• Take the MTM listener survey!

In this podcast I talk to Bonnie Bassler, a professor at Princeton and the president-elect of the American Society for Microbiology.

Bassler studies the conversations that bacteria have, using chemicals instead of words, Her research is not only helping to reveal how bacteria work together to make us sick, but also how we might interrupt their dialogue in order to cure infections.

Related Projects:

Measurement of the copy number of the master quorum-sensing regulator of a bacterial cell.

Information processing and signal integration in bacterial quorum sensing.

In this podcast, I talk to Mitchell Sogin, the Director of the Josephine Bay Paul Center for Comparative Molecular Biology and Evolution at the Marine Biological Laboratory in Wood's Hole, Massachusetts.

Dr. Sogin is one of the leaders of an ambitious project to survey the microbes of the ocean--which total over 36,000,000,000,000,000,000,000,000,000,000 cells. Using the latest DNA-sequencing technology, Dr. Sogin and his colleagues are cataloging microbes from all over the world, and are discovering a genetic diversity in the microbial world far exceeding anyone's expectations. 

Dr. Sogin explained how most species they find only exist in small numbers, while a minority of species dominate their samples. Dr. Sogin is investigating how this "rare biosphere" changes the way we understand how the ocean's ecosystems work.

Related Projects:

International Census of Marine Microbes

Woods Hole Center for Oceans and Human Health

In this podcast I talk to James Liao, a professor in the Department of Chemical and Biomolecular Engineering at UCLA. I spoke to Dr. Liao about his research into engineering microbes to make fuel.

Today, we get most of the fuel for our cars out of the ground. It's a process fraught with dangerous consequences, from the oil spill in the Gulf of Mexico to the rise in global temperatures thanks to greenhouse gases. Dr. Liao is among a growing number of scientists who think that microbes can help us out of this predicament.

We talked about the attraction of microbe-derived fuels, and the challenges of getting bacteria to turn air, water, and sun into something that can power your car.

Selected Publications

Atsumi, S.; T. Hanai and J.C. Liao (2008) Non-Fermentative Pathways for Synthesis of Branched-Chain Higher Alcohols as Biofuels, Nature, 451:86-89.

Atsumi,S.; Higashide, W.; and Liao, J.C. (2009) Direct recycling of carbon dioxide to isobutyraldehyde using photosynthesis, Nat Biotechnol, 27, 1177-1180

In this podcast, I talk to R. Ford Denison of the University of Minnesota. Denison is an evolutionary biologist who's interested in how to make agriculture better. The ways in which plants thrive or fail are shaped by their evolutionary history, as well as the evolution that unfolds every planting season.

We're most familiar with the evolution of resistance to pesticides in insects and to herbicides in weeds. But evolution has many other effects on farms. For example, many important crop plants, like soybeans, cannot extract nitrogen from the atmosphere on their own. They depend instead on bacteria that live inside their roots.

In exchange for fixed nitrogen, the bacteria get nutrients from the plants. It may seem like a happy case of cooperation, but the evolution of cooperation always runs the risk of cheating and deception. How plants and bacteria come to a compromise is a remarkable story that Denison and his colleagues are now documenting.

Selected Publications

Denison, R.F. 2010. Darwinian agriculture: where does nature's wisdom lie? Book in preparation for Princeton University Press.

Ratcliff, W.C., P. Hawthorne, M. Travisano, R.F. Denison. 2009. When stress predicts a shrinking gene pool, trading early reproduction for longevity can increase fitness, even with lower fecundity. PLoS One 4:e6055

Kiers E. T., R.A. Rousseau, S. A. West, and R. F. Denison. 2003. Host sanctions and the legume-rhizobium mutualism. Nature 425:78-81.

In this podcast, I talk with Irwin Sherman, professor emeritus at the University of California at Riverside, about the century-long quest for a vaccine against malaria.

Scientists have been trying to make a vaccine for the disease almost since the discovery of the parasite that causes malaria. Yet decade after decade, they've encountered setbacks and failures. We talked about why it's so hard to make a malaria vaccine, and how likely it is that scientists will ever be able to do so in the future.

If you want to find out more about this long-running saga, check out Sherman's new book, The Elusive Malaria Vaccine: Miracle or Mirage.

About the Book

The Elusive Malaria Vaccine: Miracle or Mirage? is based on author Irwin W. Sherman’s thorough investigation of the scientific literature as well as his first-hand interviews with today’s pioneers in malaria vaccine research. As a result, the book offers remarkable insights into the keys to a successful malaria vaccine and the obstacles hindering its development.

Malaria is one of humankind’s greatest killers, currently afflicting some 300 to 500 million people. Moreover, malaria infections have begun to spread and surge in places previously free from the disease. With the book’s easy-to-follow coverage of such topics as immunity, immunology, recombinant DNA, and monoclonal antibodies, readers gain a new understanding of the disease itself, the importance of microbe hunters, and the need for responsible leadership to face the challenges that lie ahead in the battle against malaria.

Other Publications from Dr. Sherman

Twelve Diseases That Changed Our World

The Power of Plagues

In this podcast I talk to Keith Klugman, William H. Foege Chair of Global Health at Emory University.

Dr. Klugman studies the disease that is the number one killer of children worldwide. If you guessed malaria or AIDS, you’d be wrong. It’s pneumonia. Two million children under five die every year from it every year--one child every 15 seconds.

Dr. Klugman and I spoke about his research on how pneumonia causes so much devastation, its hidden role in the 50 million deaths in the 1918 flu pandemic, and how a new pneumonia vaccine can stop the disease in its tracks. For more information on pneumonia and how we can all help fight it, visit the World Pneumonia Day web site.

Dr. Klugman's recent publications:

A role for Streptococcus pneumoniaein virus-associated pneumonia (pdf)

Levofloxacin-Resistant Invasive Streptococcus pneumoniae in the
United States: Evidence for Clonal Spread and the Impact of
Conjugate Pneumococcal Vaccine (pdf)

Dr. Peter Daszak is a disease ecologist and President of the Wildlife Trust, an international organization of scientists dedicated to the conservation of biodiversity. He is a leader in the field of conservation medicine and is well known for uncovering the wildlife origin of the SARS virus. Dr. Daszak also identifed the first case of a species extinction caused by a disease and has demonstrated a link between global trade and disease emergence via a process called "pathogen pollution."

In this interview I ask Dr. Daszak about the threat new pathogens pose to endangered species and go into detail about his discovery that chytridiomycosis, a fungal disease caused by the chytrid Batrachochytrium dendrobatidis, is responsible for global amphibian population declines. Dr. Daszack also discusses a unique study that exposes how the W.H.O. might better use their resources when faced with new pathogens such as the kind we've seen with the recent outbreak of the H1N1 virus. We also explore how pathogens of animals have the ability to evolve into human diseases like flu and HIV.

Links to research discussed in this episode:

Infectious disease and amphibian population declines (.pdf)

Emerging infectious diseases of wildlife--threats to biodiversity and human health

Wildlife Trust page about SARS

Monitoring the Deadly Nipah Virus

Assessing the Impacts of Global Wildlife Trade

In this podcast I talk to Curtis Suttle, a professor and associate dean at the University of British Columbia.Suttle studies the diversity and population of viruses across the entire planet. He has helped show that viruses are by far the most common life forms on the planet. They also contain most of the genetic diversity of life, and they even control how much oxygen we have to breathe. I talked to Suttle about coming to terms with the fact that we live on a virus planet, and how hard it is to find a place on Earth that's virus-free--even two miles underground. 

Links to Curtis Suttle and his work.

Curtis Suttle's Labatory Website

A detailed listing of Curtis Suttle's publications

In this podcast, I talk to James Collins, an investigator at the Howard Hughes Medical Institute and a professor at Boston University.

Ten years ago Collins helped launch a new kind of science called synthetic biology. I talked to Collins about the achievements of synthetic biology over the past decade, such as engineering E. coli that can count, and about the future of synthetic biology--from using bacteria to make fuel to reprogramming the bacteria in our guts to improve our health.

Nicole Dubilier, Ph.D., Director and head of the Symbiosis Department at the Max Planck Institute for Marine Microbiology, has led numerous reserach cruises and expeditions around the world studying the symbiotic relationships of bacteria and marine invertebrates. She discusses how the use of various methods, including deep-sea in situ tools, molecular, 'omic' and imaging analyses, have illuminated remarkable geographic, species and habitat diversity amongst symbionts and emphasizes the importance of discovery-driven research over hypothesis-driven methods.

Watch this episode: https://www.youtube.com/watch?v=OC9vqE1visc

• In 1878, German surgeon, botanist and microbiologist, Heinrich Anton de Bary, first described symbiosis as the living together of two or more different organisms in close physical intimacy for a longer period of time. 
• These relationships can be beneficial, detrimental or commensal, depending on the organisms involved. 
• Microbial symbiosis research holds great potential to contribute to sustainable energy production and environmental health.

• Learn more about one of Dubilier's research vessels and see videos from the expidition.
• Functional diversity enables multiple symbiont strains to coexist in deep-sea mussels.
• Chemosynthetic symbioses: Primer.
• Take the MTM listener survey!

In this episode, I talk to Michael Worobey, an associate professor at the University of Arizona.

Worobey is virus detective, gathering clues about how some of the world's deadliest pathogens have emerged and spread across the globe. Worobey and I talked about the harrowing journeys he has made in search of the origin of HIV, as well as the round-the-clock data-processing he and his colleagues used to discover the hidden history of the new H1N1 flu strain.

In this episode, I speak to Rob Knight, an assistant professor in the Department of Chemistry and Biochemistry at the University of Colorado, Boulder.

Knight studies our inner ecology: the 100 trillion microbes that grow in and on our bodies. Knight explained how hundreds of species can coexist on the palm of your hand, how bacteria manipulate your immune system and maybe even your brain, and how obesity and other health problems may come down to the wrong balance of microbes.

Worlds within worlds: evolution of the vertebrate gut microbiota.

In this episode I speak to Julian Davies, professor emeritus in the Department of Microbiology & Immunology at the University of British Columbia.

Dr. Davies is one of the world's experts on antibiotics. I talked to Davies about how the discovery of antibiotics changed the course of modern medicine, and how we now face a growing threat from the evolution of antibiotic-resistant bacteria. We also talked about some enduring mysteries about antibiotics.

Most of us think of antibiotics as a way to kill microbes. But the fact is that microbes make antibiotics naturally, and for them, these molecules may not be lethal weapons. They may actually be a way to talk to other microbes.

In this episode I speak to Sallie "Penny" Chisholm, the Lee and Geraldine Martin Professor of Environmental Studies at MIT. Dr. Chisholm studies photosynthesis—the way life harnesses the energy of the sun. Plants carry out photosynthesis, but so do microbes in the ocean. Dr. Chisholm studies the most abundant of these photosynthetic microbes, a species of bacteria called Prochlorococcus.  There are a trillion trillion Prochlrococcus on Earth. Dr. Chisholm researches these microbial lungs of the biosphere, and how they produce oxygen on which we depend.

Along with her scientific research, Dr. Chisholm is also the author of a new children's book, Living Sunlight: How Plants Bring The Earth To Life.

John Wooley is Associate Vice Chancellor of Research and Professor of Chemistry-Biochemistry and of Pharmacology at the University of California San Diego. Wooley is a leader in the young field of metagenomics: the science of gathering vast numbers of genes from the oceans, soils, air, and the human body.

A generation ago biologist knew the sequences of a few thousand genes. Since then that figure has jumped to several million genes and it's only going to continue to leap higher in years to come. This wealth of data is allowing scientists to get answers to fundamental questions they rarely even asked a generation ago.

They're starting to understand how thousands of species of microbes coexist in our bodies. They're investigating how hundreds of genes work together inside a single cell and they're starting to get a vision of the full diversity of the billions of proteins that life produces, what scientists sometimes call the protein universe.

John Wooley has been at the center of this revolution, investigating some of these new questions and leading pioneering projects such as CAMERA, the Community Cyberinfrastructure for Advanced Marine Microbial Ecology Research and Analysis, to organize the unprecedented amount of data that scientists have at their disposal so that they can master that data rather than drown in it.

In this episode I spoke to Wooley about how metagenomics has revolutionized research on everything from marine ecology to human health, and how he and his colleagues cope with an influx of data on millions of new genes.

In this episode I talk with Paul Turner, an associate professor of ecology and evolutionary biology at Yale University.

2009 saw the emergence of a new strain of H1N1 flu. Scientists soon determined that the virus had leaped from pigs to humans and then spread to millions of people.

When viruses make this kind of leap it's a reason to worry. In 1918 when a strain of flu leapt from birds to humans, 50 million people died in a matter of months. So far the new H1N1 flu strain is behaving like a relatively ordinary flu. Still even ordinary flu is a matter of serious concern. Over 4,000 people in the US alone have died from the new H1N1 flu strain and scientists can't say for sure what it would take to turn this new strain into a global killer.

It's a sobering reminder of how mysterious virus evolution remains. Over the past century a number of viruses have made the leap from animal host to humans including SARS and HIV and scientists worry that the next great plague may be a virus that we don't even know about yet.

Paul Turner is learning how new viruses emerge by watching them evolve in his lab. Fortunately the viruses he studies don't make you sick. Instead they attack E-coli and other single celled hosts. But these viruses are teaching Turner and his colleagues about some of the fundamental rules that govern how viruses evolve to attack new hosts. Turner hopes that what he and his colleagues learn about those rules may help future generations of scientists fight against the next generation of viruses that can make us sick.

Jonathan Eisen is a professor at the University of California, Davis Genome Center. Over the course of his career, he has pioneered new ways of sequencing microbial genomes and analyzing them.

I talked to Eisen about some of the weirdest creatures he's studied, such as bacteria that only live on the bellies of worms at the bottom of the ocean, and how we may be able to exploit their genomes for our own benefit. We also discussed the new movement for open access to scientific literature, a subject that's a particular passion of Eisen, who is academic editor in chief at the open-access journal PLOS Biology.

Hazel Barton is the Ashland Professor of Integrative Science at Northern Kentucky. She explores some of the world's most remote caves to study the remarkable diversity of microbes that thrive in their dark rececesses. I spoke to Barton about how she first became captivated by these bizarre organisms, what it's like to do delicate microbiology when you're hip-deep in mud, and why she wants to explore caves on Mars in search of Martians.

Dennis Bray is an active professor emeritus in both the Department of Physiology and Department of Neuroscience at the University of Cambridge. He studies the behavior of microbes--how they "decide" where to swim, when to divide, and how best to manage the millions of chemical reactions taking place inside their membranes. For Bray, microbes are tiny, living computers, with genes and proteins serving the roles of microprocessors.

Michael Cunliffe is a microbiologist in the Department of Biological Sciences at the University of Warwick in England. He studies the microbes that live in the thin layer of water at the very surface of the ocean. His research is shedding light on an ecosystem that's both mysterious and huge, spanning three-quarters of the surface of the planet.

In this interview, I talked with Cunliffe about the discovery of this sea-surface ecosystem, and the influence it has over the Earth's climate.

From Bovine Spongiform Encephalopathy (BSE) to Creutzfeldt-Jakob disease (CJD), Neil Mabbott, Ph.D., has worked for nearly 2 decades on understanding the mechanisms by which prion proteins become infectious and cause neurological disease in humans and animals. He discusses the remarkable properties of prions and addresses complexities surrounding symptoms, transmission and diagnosis of prion disease.

Pratik Shah is a graduate student in the Department of Microbiology at the University of Mississippi Medical Center in Jackson, and he’s a 2009 recipient of ASM’s Raymond W. Sarber award, granted to recognize students for research excellence and potential.

His research focuses on polyamines and polyamine biosynthesis and transport systems in Streptococcus pneumoniae.  He’s studying polyamines with the goal of finding potential targets for pneumococcal vaccines and prophylactic interventions against pneumococcal disease.  

In this interview, I talked with Pratik about why polyamines may hold the key for new ways to combat pathogens, his plans for the future, and about advice he would give to young people considering grad school.

Abigail Salyers is a Professor of Microbiology and the G. William Arends Professor of Molecular and Cell Biology at the University of Illinois at Urbana-Champaign, and her research focuses on the ecology of microorganisms in the human body and the comings and goings of antibiotic resistance genes, particularly genes in Bacteroides species.  Dr. Salyers is ASM’s 2009 Graduate Microbiology Teaching Awardee. 

If you’ve ever tried teaching or mentoring, you know it’s not always easy, but for an eminent scientist, teaching at the undergraduate or graduate level must be incredibly difficult.  After all, once you reach a certain level of knowledge in any field, it can be hard to relate your knowledge to people who know relatively little about it.  Dr. Salyers has tackled 100-level biology courses with as many as 300 students, taught one-on-one at the lab bench, and been an instructor at an intensive summer course in microbial diversity, all while rising to the top of her field in research. 

In this interview, I talked with Dr. Salyers about the most influential teacher in her own life (you might be surprised to learn who that is), about whether antibiotic resistance is getting the kind of play it deserves, and about why the baboon vagina is an interesting study system.

Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist.  His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. 

In his work, Mr. Guruswamy places a lot of emphasis on helping others.  A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis.  Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. 

Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than $50 in his pocket. 

In this interview, I asked Mr. Guruswamy about his work at the state lab in Virginia, about tuberculosis in this country, and about why he saw more unusual clinical cases during his time working at the Mayo Clinic in Minnesota than he has during any other phase of his career.